Rudolf Jaenisch awarded Ogawa-Yamanaka Stem Cell Prize

Rudolf Jaenisch is recognized for his trailblazing contributions to epigenetics and stem cell biology, which have shaped modern regenerative medicine.

Sarah Stanley | Gladstone Institutes
August 28, 2025

Rudolf Jaenisch, MD, was announced today as the recipient of the 2025 Ogawa-Yamanaka Stem Cell Prize by Gladstone Institutes. He was selected for his trailblazing contributions to epigenetics and stem cell biology. His pivotal discoveries have profoundly advanced our understanding of gene regulation, cellular reprogramming, and the potential of regenerative medicine.

A founding member of the Whitehead Institute for Biomedical Research in Cambridge, Massachusetts, Jaenisch is also a professor of biology at the Massachusetts Institute of Technology. He is widely recognized for his role in establishing the use in science of induced pluripotent stem (iPS) cells—adult cells that have been reprogrammed into an embryonic stem cell–like state with the potential to become any cell type in the body.

Among his many achievements, Jaenisch was the first to show the potential therapeutic applications of iPS cells after they were discovered by Gladstone Senior Investigator Shinya Yamanaka, MD, PhD. In fact, Jaenisch effectively cured mice of sickle cell anemia by using iPS cells that had been derived from the animals’ own skin cells and in which the disease-causing genetic defect had been corrected.

“Until then, iPS cells were just an exciting lab tool—but Dr. Jaenisch provided the first real proof that they could be used to treat human disease,” says Deepak Srivastava, MD, chair of the selection committee, president of Gladstone Institutes, and director of the Rodenberry Stem Cell Center at Gladstone. “We’re very happy to recognize his outstanding career with this year’s award. His many contributions to stem cell research and disease modeling have helped shape modern regenerative medicine as we know it.”

Jaenisch has been at the forefront of exploring, expanding, and refining the processes by which iPS cells are created and applied in labs around the world. His work has opened the door to the development of therapies for a wide range of genetic and degenerative diseases.

Since its establishment in 2015, the Ogawa-Yamanaka Stem Cell Prize has honored scientists and doctors leading groundbreaking work in translational regenerative medicine using reprogrammed cells. Each year, it is made possible by a generous gift from the Hiro and Betty Ogawa family.

The prize, supported by Gladstone and Cell Press, also pays tribute to Yamanaka, whose discovery of iPS cells earned him a Nobel Prize in 2012 and is tightly intertwined with Jaenisch’s work.

“Shinya’s discovery completely transformed the world of stem cell science and opened up so many promising new paths for understanding and addressing disease,” Jaenisch says. “What an honor it is to be recognized for my contributions in this field.”

One of Jaenisch’s earliest marks on science came in 1974, when he co-created the first transgenic animal—an organism whose genetic material has been intentionally altered by adding foreign genes—with pioneering embryologist Beatrice Mintz, PhD. This work became the foundation for genetically engineered animal models, which are used in nearly every area of biomedical research today.

“This single study was a major leap in molecular biology,” says Srivastava. “It gave birth to the very concept of modeling human diseases in animals, allowing scientists to deliberately change an animal’s genetic code in order to study the mechanisms of disease and test therapies.”

In his more than 40 years at the Whitehead Institute, Jaenisch has led research exploring how stem cells and reprogramming technologies could be harnessed to better understand and treat disease. In the process, he has continued to develop innovative tools, including adapting CRISPR technology for gene editing and epigenome editing in stem cell systems.

An independent committee of international stem cell experts selected Jaenisch for the 2025 Ogawa-Yamanaka Stem Cell Prize from a highly competitive pool of nominees. As this year’s winner, he will receive an unrestricted prize of $150,000. Gladstone will host a ceremony on December 1, 2025, in San Francisco, California, where Jaenisch will deliver a scientific lecture and be presented with the award.

About Gladstone Institutes

Gladstone Institutes is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. Established in 1979, it is located in the epicenter of biomedical and technological innovation, in the Mission Bay neighborhood of San Francisco. Gladstone has created a research model that disrupts how science is done, funds big ideas, and attracts the brightest minds.

About Rudolf Jaenisch

Rudolf Jaenisch, MD, is a founding member of the Whitehead Institute for Biomedical Research and a professor of biology at the Massachusetts Institute of Technology. He is a pioneer of transgenic science, in which an animal’s genetic makeup is altered.

Jaenisch received his MD from the University of Munich in 1967 and carried out postdoctoral research at Princeton University, Fox Chase Institute for Cancer Research, and the Salk Institute. Before joining Whitehead in 1982, he was head of the Department of Tumor Virology at the Heinrich Pette Institute at the University of Hamburg.

His current research focuses on the epigenetic regulation of gene expression, which has led to major advances in creating embryonic stem cells and iPS cells, as well as their therapeutic applications. His lab also focuses on the epigenetic mechanisms involved in cancer and brain development, as well as coronavirus biology.

Jaenisch has co-authored more than 500 research papers and received various awards during his career, including the Max Delbrück Medal, the Vilcek Prize, the National Medal of Science, the Wolf Prize in Medicine, and the Otto Warburg Medal. He is a fellow of the American Academy of Arts and Sciences and an elected member of the U.S. National Academy of Sciences. He also was president of the International Society for Stem Cell Research in 2014–15.

About the Ogawa-Yamanaka Stem Cell Prize

The Ogawa-Yamanaka Stem Cell Prize recognizes individuals whose original translational research has advanced cellular reprogramming technology for regenerative medicine. Supported by Gladstone Institutes, in partnership with Cell Press, the prize was established in 2015 through a generous gift from Betty and Hiro Ogawa. It has been maintained through their sons, Andrew and Marcus Ogawa, to honor the Ogawas’ memory by continuing the philanthropic legacy they shared during their 46-year marriage. It also recognizes the importance of induced pluripotent stem cells (iPS cells), discovered by Gladstone Senior Investigator and Nobel laureate Shinya Yamanaka, MD, PhD.

Past recipients include Masayo Takahashi, MD, PhD, in 2015; Douglas Melton, PhD, in 2016; Lorenz Studer, MD, in 2017; Marius Wernig, MD, PhD, in 2018; Gordon Keller, PhD, in 2019; Juan Carlos Izpisua Belmonte, PhD, in 2022; Magdalena Zernicka-Goetz, PhD, in 2023; and Rusty Gage, PhD, in 2025.

The 2025 selection committee was composed of George Daley, MD, PhD, dean of Harvard Medical School; Hideyuki Okano, MD, PhD, dean of the School of Medicine at Keio University; Deepak Srivastava, MD, president of Gladstone Institutes and director of the Roddenberry Stem Cell Center at Gladstone; Lorenz Studer, MD, director of the Center for Stem Cell Biology at Memorial Sloan Kettering Cancer Center; Fiona Watt, FRS, FMedSci, director of the Centre for Stem Cells and Regenerative Medicine at King’s College, London; and Shinya Yamanaka, MD, PhD, senior investigator at Gladstone and director emeritus of the Center for iPS Cell Research and Application at Kyoto University.

3 Questions: Mariely Morales Burgos on the BSG-MSRP-Bio program

Undergraduate student and Gould Fellow discusses choosing a summer research lab, living in the Greater Boston Area, and managing imposter syndrome.

Lillian Eden | Department of Biology
August 28, 2025

Mariely Morales Burgos first fell in love with MIT while participating in the Quantitative Methods Workshop, a weeklong intensive offered in January to prepare students to analyze data in biology and neuroscience. Those skills have come in handy this summer while participating in the Bernard S. and Sophie G. Gould MIT Summer Research Program in Biology (BSG-MSRP-Bio), a ten-week training program for non-MIT undergraduate students interested in pursuing an academic career.

A Gould Fellow and McNair Scholar, Morales Burgos spent the summer mentored by Associate Professor of Biology Eliezer Calo, for whom the program served as a critical stepping stone in his own career. Calo is the first BSG-MSRP-Bio program alum to receive tenure at MIT. 

A rising senior at the University of Puerto Rico at Aguadilla, Morales Burgos spent the summer using zebrafish to study the molecular machinery responsible for making proteins. 

Three people standing in an interior lab space smiling at the camera
(from right to left) Mariely Morales Burgos, mentor and Associate Professor of Biology Eliezer Calo, and Adriana Camacho-Badillo in the lab at MIT. Camacho-Badillo, a returning BSG-MSRP-Bio student, encouraged Morales Burgos to apply for the program. Photo Credit: Mandana Sassanfar/MIT Department of Biology.

Q: How did you select your lab, and what have you been working on?

A: I knew I wanted to work in Eliezer’s lab after meeting him during a QMW faculty lunch. I felt like we really connected because of his genuine passion for science, commitment to his trainees, and the way he spoke about his lab and the care he puts into mentoring. 

My research focuses on ribosomes, which are the protein factories of the cell, and they’re essential to make what the cell needs to go through different developmental stages and through its most crucial processes. In early development, zebrafish and numerous other organisms depend on maternally deposited ribosomes and associated molecular components inherited directly from the oocyte. As time goes on, their own genomes activate, and they start being able to make their own ribosomes. What I’m studying is this transition from maternal to zygotic ribosomes during early development. We know this transition happens, but we don’t know how this transition is regulated, whether it happens passively, through dilution, or actively, through targeted cellular mechanisms.  

One skill that I’ve been able to learn here, other than just learning and applying techniques, is how to develop a whole project independently, how to think critically about the next step of my project, and what other questions I can ask.

Being able to work with a live animal organism and see the developmental stages in real-time, I thought that was really cool. And it really makes me appreciate the beauty of developmental biology, and just life in general.

Q: How did you prepare for the program, and what has it been like living and working in Boston and Cambridge? As a Gould Fellow, you also met with program supporters Mike Gould and Sara Moss, who established the Bernard S. and Sophie G. Gould fund to honor the memory of Mike’s parents. What was it like to meet and talk to Mike and Sara? 

A: Once we get accepted, we’re encouraged to start communication with our faculty. I had a few meetings with Eliezer to discuss some papers, and based on our discussion and the expectations for the project, I was able to read more and start preparing before I arrived.

Every few weeks beforehand, we had a meeting with Mandana and the rest of the cohort on Zoom, and we were talking on an app called GroupMe, and we exchanged socials, so when we came here, we weren’t complete, total strangers. 

When I’m not in the lab, I spend a lot of time with my roommates, and we like walking around Boston. It’s a very walkable city and has a lot of unique architecture, but Boston weather is very unpredictable. I’m from a tropical island, so I wish someone had told me to prepare for the rain and cold, but the July weather has been so nice. 

In Puerto Rico, you don’t have public transportation, so I’ve really enjoyed commuting. Our dorms are at Northeastern, so I take the bus, and it goes over the Charles, and it’s so beautiful. 

I’m a person who feels a lot of emotions, so I was the only one who cried when we met the Goulds. It was a bit embarrassing, but that’s okay. They told me to never lose the empathy that I have, no matter how hard my journey is, to keep on holding on to my sentimental side and keep working hard, and they’re so excited to see where we end up and what we end up doing.

Mariely Morales Burgos standing in front of a paper poster, indicating a certain point of data to three people
The summer research intensive culminated in a lively poster session. Photo Credit: Lillian Eden/MIT Department of Biology

Q: This program’s aim is to make research available for students who don’t have access to hands-on experience at their home institutions, so many students, including you, are embarking on independent research projects for the first time, which could trigger “imposter syndrome.” What was that experience like for you, and what advice would you give to future BSG-MSRP-Bio program participants? 

A: I was a little bit intimidated by the program, and didn’t apply the first time I had the opportunity. Then I did the Quantitative Methods Workshop, and those eight days were beautiful. I got to see how everybody loves collaborating and that the community here is very supportive. I met many wonderful faculty who were passionate about their research, and that exposure made me realize I would love to be part of a place like this. 

Imposter syndrome is something that I feel like most everybody deals with, but MSRP is a place that, if you’re willing to put in the work, everyone is willing to help you reach the places that you dream of being. It might feel intimidating to ask questions, and you could be scared of feeling like you don’t deserve to be in these spaces. But somebody who wants you to grow will answer your questions. I wanted to be able to work independently as soon as possible, because that really showcases your abilities, but no matter what, Eliezer, who’s mentoring me, his door is always open. 

What I advise is to really dive into your project and take advantage of everything this program offers. Working hard on your project, you get to fall in love with the process and the questions you’re trying to answer and science as a whole, and there’s nothing better than to spend the summer on a project that you love.

Locally produced proteins help mitochondria function

One of the ways that cells ensure proteins end up where they're needed is creating them at that location, through a process called localized translation. New research from the Weissman Lab has expanded our understanding localized translation at mitochondria and sheds light on the organizational principles of genes and the proteins they encode.

Greta Friar | Whitehead Institute
August 27, 2025

Now, Weissman, who is also a professor of biology at the Massachusetts Institute of Technology and an HHMI Investigator, and postdoc in his lab Jingchuan Luo have expanded our knowledge of localized translation at mitochondria, structures that generate energy for the cell. In a paper published in Cell on August 27, they share a new tool, LOCL-TL, for studying localized translation in close detail, and describe the discoveries it enabled about two classes of proteins that are locally translated at mitochondria.

The importance of localized translation at mitochondria relates to their unusual origin. Mitochondria were once bacteria that lived within our ancestors’ cells. Over time the bacteria lost their autonomy and became part of the larger cells, which included migrating most of their genes into the larger cell’s genome in the nucleus. Cells evolved processes to ensure that proteins needed by mitochondria that are encoded in genes in the larger cell’s genome get transported to the mitochondria. Mitochondria retain a few genes in their own genome, so production of proteins from the mitochondrial genome and that of the larger cell’s genome must be coordinated to avoid mismatched production of mitochondrial parts. Localized translation may help cells to manage the interplay between mitochondrial and nuclear protein production—among other purposes.

How to detect local protein production

For a protein to be made, genetic code stored in DNA is read into RNA, and then the RNA is read or translated by a ribosome, a cellular machine that builds a protein according to the RNA code. Weissman’s lab previously developed a method to study localized translation by tagging ribosomes near a structure of interest, and then capturing the tagged ribosomes in action and observing the proteins they are making. This approach, called proximity-specific ribosome profiling, allows researchers to see what proteins are being made where in the cell. The challenge that Luo faced was how to tweak this method to capture only ribosomes at work near mitochondria.

Ribosomes work quickly, so a ribosome that gets tagged while making a protein at the mitochondria can move on to making other proteins elsewhere in the cell in a matter of minutes. The only way researchers can guarantee that the ribosomes they capture are still working on proteins made near the mitochondria is if the experiment happens very quickly.

Weissman and colleagues had previously solved this time sensitivity problem in yeast cells with a ribosome-tagging tool called BirA that is activated by the presence of the molecule biotin. BirA is fused to the cellular structure of interest, and tags ribosomes it can touch—but only once activated. Researchers keep the cell depleted of biotin until they are ready to capture the ribosomes, to limit the time when tagging occurs. However, this approach does not work with mitochondria in mammalian cells because they need biotin to function normally, so it cannot be depleted.

Luo and Weissman adapted the existing tool to respond to blue light instead of biotin. The new tool, LOV-BirA, is fused to the mitochondria’s outer membrane. Cells are kept in the dark until the researchers are ready. Then they expose the cells to blue light, activating LOV-BirA to tag ribosomes. They give it a few minutes and then quickly extract the ribosomes. This approach proved very accurate at capturing only ribosomes working at mitochondria.

The researchers then used a method originally developed by the Weissman lab to extract the sections of RNA inside of the ribosomes. This allows them to see exactly how far along in the process of making a protein the ribosome is when captured, which can reveal whether the entire protein is made at the mitochondria, or whether it is partly produced elsewhere and only gets completed at the mitochondria.

“One advantage of our tool is the granularity it provides,” Luo says. “Being able to see what section of the protein is locally translated helps us understand more about how localized translation is regulated, which can then allow us to understand its dysregulation in disease and to control localized translation in future studies.”

Two protein groups are made at mitochondria

Using these approaches, the researchers found that about twenty percent of the genes needed in mitochondria that are located in the main cellular genome are locally translated at mitochondria. These proteins can be divided into two distinct groups with different evolutionary histories and mechanisms for localized translation.

One group consists of relatively long proteins, each containing more than 400 amino acids or protein building blocks. These proteins tend to be of bacterial origin—present in the ancestor of mitochondria—and they are locally translated in both mammalian and yeast cells, suggesting that their localized translation has been maintained through a long evolutionary history.

Like many mitochondrial proteins encoded in the nucleus, these proteins contain a mitochondrial targeting sequence (MTS), a zip code that tells the cell where to bring them. The researchers discovered that most proteins containing an MTS also contain a nearby inhibitory sequence that prevents transportation until they are done being made. This group of locally translated proteins lacks the inhibitory sequence, so they are brought to the mitochondria during their production.

Production of these longer proteins begins anywhere in the cell, and then after approximately the first 250 amino acids are made, they get transported to the mitochondria. While the rest of the protein gets made, it is simultaneously fed into a channel that brings it inside the mitochondria. This ties up the channel for a long time, limiting import of other proteins, so cells can only afford to do this simultaneous production and import for select proteins. The researchers hypothesize that these bacterial-origin proteins are given priority as an ancient mechanism to ensure that they are accurately produced and placed within mitochondria.

The second locally translated group consists of short proteins, each less than 200 amino acids long. These proteins are more recently evolved, and correspondingly, the researchers found that the mechanism for their localized translation is not shared by yeast. Their mitochondrial recruitment happens at the RNA level. Two sequences within regulatory sections of each RNA molecule that do not encode the final protein instead code for the cell’s machinery to recruit the RNAs to the mitochondria.

The researchers searched for molecules that might be involved in this recruitment, and identified the RNA binding protein AKAP1, which exists at mitochondria. When they eliminated AKAP1, the short proteins were translated indiscriminately around the cell. This provided an opportunity to learn more about the effects of localized translation, by seeing what happens in its absence. When the short proteins were not locally translated, this led to the loss of various mitochondrial proteins, including those involved in oxidative phosphorylation, our cells’ main energy generation pathway.

In future research, Weissman and Luo will delve deeper into how localized translation affects mitochondrial function and dysfunction in disease. The researchers also intend to use LOCL-TL to study localized translation in other cellular processes, including in relation to embryonic development, neural plasticity, and disease.

“This approach should be broadly applicable to different cellular structures and cell types, providing many opportunities to understand how localized translation contributes to biological processes,” Weissman says. “We’re particularly interested in what we can learn about the roles it may play in diseases including neurodegeneration, cardiovascular diseases, and cancers.”

Luo et al. “Proximity-specific ribosome profiling reveals the logic of localized mitochondrial translation.” Cell, August 27, 2025. https://doi.org/10.1016/j.cell.2025.08.002

Can bacteria be used to clean up oil spills?

The Drennan Lab is working on insights into how nature performs challenging chemistry in oxygen-free environments, with potential applications for remediation, such as cleaning up oil spills, in situations where traditional approaches are ineffective.

Produced by Lillian Eden | Department of Biology
August 28, 2025

Can bacteria clean up oil spills? The short answer: no. Or, at least, not yet.

The Drennan Lab is working to understand how bacteria perform incredible, radical chemistry on inert compounds. Inert compounds, like those that make up crude oil, are challenging to break down because they contain very stable chains of carbon and hydrogen (hydrocarbons). Some microbes have special enzymes that attach another compound to these long, hydrocarbon chains, which makes it possible for the previously inert compound to be degraded. 

Using cryo-electron microscopy, the Drennan Lab recently determined the three-dimensional structure of a glycyl radical enzyme that catalyzes the formation of carbon-carbon bonds, outlined in a recent paper published in PNAS.

This work provides insights into how nature performs challenging chemistry in oxygen-free environments and has potential applications for remediation, such as cleaning up oil spills, in situations where traditional approaches are ineffective. 

This research was led by former postdoc Mary C. Andorfer, who will continue to explore the power of anaerobic microbes as an Assistant Professor at Michigan State University. This work was funded by the National Institutes of Health. Catherine Drennan is a Professor of Biology and Chemistry at MIT and a Howard Hughes Medical Institute Investigator. 

2025 Amon Award Winners Announced

Congratulations to the winners of the 2025 Angelika Amon Young Scientist Award: Sourav Ghosh of the Indian Institute of Technology Bombay, and Kotaro Tomuro of RIKEN and The University of Tokyo.

Koch Institute
August 12, 2025

Established in 2021, the Angelika Amon Young Scientist Award recognizes graduate students in the life sciences or biomedical research from institutions outside the United States who embody Dr. Amon’s infectious enthusiasm for discovery science.

Sourav Ghosh, a PhD student in Biotechnology at the Indian Institute of Technology Bombay under the supervision of Anirban Banerjee, investigates cell-autonomous immunity—the ability of host cells to defend themselves against intracellular pathogens. His work uncovered a unique bacteriolytic role for VCP/p97, a host AAA-ATPase or enzyme that uses mechanical force to extract ubiquitinated proteins from bacterial surfaces, rupturing the pathogens and releasing their contents. This process protects the host from lethal sepsis and reveals VCP/p97 as a broad-spectrum defense effector. Ghosh’s findings, published in Nature Microbiology, open new avenues for therapeutic interventions against bacterial infections.

Kotaro Tomuro, a PhD candidate at the RIKEN Pioneering Research Institute and the Graduate School of Frontier Sciences at The University of Tokyo, works under the supervision of Shintaro Iwasaki. Tomuro develops cutting-edge ribosome profiling methods to investigate the spatial and temporal regulation of translation—the process by which genetic information is converted into proteins. His innovations include “Ribo-Calibration,” an approach that enables absolute quantification of translation rates, and “APEX-Ribo-Seq,” which profiles protein synthesis within specific cellular compartments. Together, these tools have generated a detailed atlas of where and when proteins are made in the cell, revealing new principles of gene expression with potential applications in neurobiology, cancer research, and RNA-based therapeutics.

Ghosh and Tomuro will present their research at the Amon Award ceremony on Thursday, November 6, at 10 a.m. in the Luria Auditorium, followed by an 11:30 a.m. reception in the Koch Institute Public Galleries.

The MIT community and Amon Lab alumni are invited to attend.

Can a pill help you live longer? The science behind NAD and longevity

MIT professor, Dr. Leonard Guarente, conducts research into sirtuin genes and the power of a molecule called NAD.

WCVB
July 22, 2025

It might sound too good to be true: a pill that could help you live a longer, healthier life. But Leonard Guarente, a longtime MIT biologist, believes the idea holds promise.

Guarente, the Novartis Professor of Biology at MIT, has spent more than 40 years studying the science of aging. He started small, working with yeast cells.

“We decided to look for genes that could make yeast live longer,” he said. That’s when a gene called SIR2 caught his attention. Boosting SIR2 activity helped yeast cells live longer—and when the same effect was observed in roundworms, Guarente turned his attention to humans.

Humans, it turns out, have seven genes similar to SIR2. Collectively, these are called sirtuins, a group of proteins essential to cell health. According to Guarente, sirtuins help power cells, repair damage, and regulate which genes are turned on or off.

Guarente says sirtuins need NAD (nicotinamide adenine dinucleotide) to stay active, but NAD levels naturally decline as we get older.

“If we could restore NAD levels in an older person back to youthful levels, we thought that would do a lot of good,” he explained.

That idea became the foundation for Elysium Health, a company Guarente co-founded. Some critics question the ethics of a scientist selling supplements based on his own research, but Guarente stands by the rigor of his approach. “We ended up with eight Nobel Prize winners on the board,” he noted.

Of course, whether restoring NAD levels leads to longer life is still uncertain. “A person who is very healthy might not notice much initially because where is there to go?” Guarente explained. “But what about in 30 years? There’s no way to answer that question right now.”

Mapping cells in time and space: a new tool reveals a detailed history of tumor growth

Weissman and colleagues have developed an advanced lineage tracing tool that not only captures an accurate family tree of cell divisions, but also combines that with spatial information: identifying where each cell ends up within a tissue.

Greta Friar | Whitehead Institute
July 24, 2025

All life is connected in a vast family tree. Every organism exists in relationship to its ancestors, descendants, and cousins, and the path between any two individuals can be traced. The same is true of cells within organisms—each of the trillions of cells in the human body is produced through successive divisions from a fertilized egg, and can all be related to one another through a cellular family tree. In simpler organisms such as the worm C. elegans, this cellular family tree has been fully mapped, but the cellular family tree of a human is many times larger and more complex.

In the past, Whitehead Institute Member Jonathan Weissman and other researchers have developed lineage tracing methods to track and reconstruct the family trees of cell divisions in model organisms in order to understand more about the relationships between cells and how they assemble into tissues, organs, and—in some cases—tumors. These methods could help to answer many questions about how organisms develop and diseases like cancer are initiated and progress.

Now, Weissman and colleagues have developed an advanced lineage tracing tool that not only captures an accurate family tree of cell divisions, but also combines that with spatial information: identifying where each cell ends up within a tissue. The researchers used their tool, PEtracer, to observe the growth of metastatic tumors in mice. Combining lineage tracing and spatial data provided the researchers with a detailed view of how elements intrinsic to the cancer cells and from their environments influenced tumor growth, as Weissman and postdocs in his lab Luke Koblan, Kathryn Yost, and Pu Zheng, and graduate student William Colgan share in a paper published in the journal Science on July 24.

“Developing this tool required combining diverse skillsets through the sort of ambitious interdisciplinary collaboration that’s only possible at a place like Whitehead Institute,” says Weissman, who is also a professor of biology at the Massachusetts Institute of Technology and an HHMI Investigator. “Luke came in with an expertise in genetic engineering, Pu in imaging, Katie in cancer biology, and William in computation but the real key to their success was their ability to work together to build PEtracer.”

“Understanding how cells move in time and space is an important way to look at biology, and here we were able to see both of those things in high resolution. The idea is that by understanding both a cell’s past and where it ends up, you can see how different factors throughout its life influenced its behaviors. In this study we use these approaches to look at tumor growth, though in principle we can now begin to apply these tools to study other biology of interest like embryonic development,” Koblan says.

Designing a tool to track cells in space and time

PEtracer tracks cells’ lineages by repeatedly adding short, predetermined codes to the DNA of cells over time. Each piece of code, called a lineage tracing mark, is made up of 5 bases, the building blocks of DNA. These marks are inserted using a gene editing technology called prime editing, which directly rewrites stretches of DNA with minimal undesired byproducts. Over time, each cell acquires more lineage tracing marks, while also maintaining the marks of its ancestors. The researchers can then compare cells’ combinations of marks to figure out relationships and reconstruct the family tree.

“We used computational modeling to design the tool from first principles, to make sure that it was highly accurate, and compatible with imaging technology. We ran many simulations to land on the optimal parameters for a new lineage tracing tool, and then engineered our system to fit those parameters,” Colgan says.

When the tissue—in this case, a tumor growing in the lung of a mouse—had sufficiently grown, the researchers collected these tissues and used advanced imaging approaches to look at each cell’s lineage relationship to other cells via the lineage tracing marks, along with its spatial position within the imaged tissue and its identity (as determined by the levels of different RNAs expressed in each cell). PEtracer is compatible with both imaging approaches and sequencing methods that capture genetic information from single cells.

“Making it possible to collect and analyze all of this data from the imaging was a large challenge,” Zheng says. “What’s particularly exciting to me is not just that we were able to collect terabytes of data, but that we designed the project to collect data that we knew we could use to answer important questions and drive biological discovery.”

Reconstructing the history of a tumor

Combining the lineage tracing, gene expression, and spatial data let the researchers understand how the tumor grew. They could tell how closely related neighboring cells are and compare their traits. Using this approach, the researchers found that the tumors they were analyzing were made up of four distinct modules, or neighborhoods, of cells.

The tumor cells closest to the lung, the most nutrient-dense region, were the most fit, meaning their lineage history indicated the highest rate of cell division over time. Fitness in cancer cells tends to correlate to how aggressively tumors will grow.

The cells at the “leading edge” of the tumor, the far side from the lung, were more diverse and not as fit. Below the leading edge was a low-oxygen neighborhood of cells that might once have been leading edge cells, now trapped in a less desirable spot. Between these cells and the lung-adjacent cells was the tumor core, a region with both living and dead cells as well as cellular debris.

The researchers found that cancer cells across the family tree were equally likely to end up in most of the regions, with the exception of the lung adjacent region, where a few branches of the family tree dominated. This suggests that the cancer cells’ differing traits were heavily influenced by their environments, or the conditions in their local neighborhoods, rather than their family history. Further evidence of this point was that expression of certain fitness-related genes, such as Fgf1/Fgfbp1, correlated to a cell’s location rather than its ancestry. However, lung adjacent cells also had inherited traits that gave them an edge, including expression of the fitness-related gene Cldn4­—showing that family history influenced outcomes as well.

These findings demonstrate how cancer growth is influenced both by factors intrinsic to certain lineages of cancer cells and by environmental factors that shape the behavior of cancer cells exposed to them.

“By looking at so many dimensions of the tumor in concert, we could gain insights that would not have been possible with a more limited view,” Yost says. “Being able to characterize different populations of cells within a tumor will enable researchers to develop therapies that target the most aggressive populations more effectively.”

“Now that we’ve done the hard work of designing the tool, we’re excited to apply it to look at all sorts of questions in health and disease, in embryonic development, and across other model species, with an eye toward understanding important problems in human health,” Koblan says. “The data we collect will also be useful for training AI models of cellular behavior. We’re excited to share this technology with other researchers and see what we all can discover.”

Luke W. Koblan, Kathryn E. Yost, Pu Zheng, William N. Colgan, Matthew G. Jones, Dian Yang, Arhan Kumar, Jaspreet Sandhu, Alexandra Schnell, Dawei Sun, Can Ergen, Reuben A. Saunders, Xiaowei Zhuang, William E. Allen, Nir Yosef, Jonathan S. Weissman. “High-resolution spatial mapping of cell state and lineage dynamics in vivo with PEtracer.” Science, online July 24, 2025. https://doi.org/10.1126/science.adx3800

Ophthalmologist Puts Mind and Hand to Art

Carmel Mercado ’09 describes herself as “existing at the intersection of health and art.” A Seattle-based pediatric ophthalmologist, Mercado is also a visual artist whose whimsical illustrations and colorful animal characters can be found in places as varied as a children’s hospital and a microbrewery.

Sara Shay | MIT Technology Review
July 26, 2025

Carmel Mercado ’09 describes herself as “existing at the intersection of health and art.” A Seattle-based pediatric ophthalmologist, Mercado is also a visual artist whose whimsical illustrations and colorful animal characters can be found in places as varied as a children’s hospital and a microbrewery.

Looking back, Mercado says that even as a premed biology major at MIT she was pursuing both paths. She took a First-Year Advising Seminar in the arts and found a mentor in Michèle Oshima, then director of student and artist-in-residence programs at MIT’s Office of the Arts, who encouraged her to apply for the MIT Arts Scholars program. That gave her the opportunity to showcase her work in a gallery at MIT.

Mercado’s next stop was medical school at Johns Hopkins (she graduated in 2014). There, too, she gravitated toward opportunities for artistic expression, such as designing T-shirts and posters for an event welcoming prospective students. “That kind of helped me get through some darker days when I was really tired or really overwhelmed by the medical part of it,” she says.

She chose ophthalmology as her specialty in part because she found the eye itself visually appealing. “The first time I saw the fundus, the retina, the back of the eye, it was so beautiful to me,” she says. “Just looking at the optic nerve, the colors, the placement, I thought about how amazing it is that we can get such beautiful and complex imagery of our world from what looks to most people like a blob of jelly.”

Initially, Mercado assumed art would take a backseat to her medical career, but time in Japan—including a MISTI summer internship in Kobe—led her to realize she had other options. She connected with a mentor, Kenji Watanabe, while studying the history of medicine at Keio University in Tokyo during medical school. Watanabe “showed me a very different lifestyle,” she says: He didn’t limit his work to academia. “He had this really cool niche where he could do all this policy work. He was traveling to different countries to meet up with other physicians. It was eye-opening,” Mercado says. “He made me realize you can shape your career and your life to be able to pursue your passions. You shouldn’t just accept the traditional way. Being exposed to that early on probably gave me the courage to do what I’m doing now.”

As a practicing ophthalmologist, she began to involve art in her work by designing patient materials featuring characters she created. Colleagues noticed and offered her commissions. About four years ago, Mercado decided to pursue art full-time. The problem: She wasn’t sure how to promote herself. “I just about tried everything to see what would stick,” she says. She started an Etsy page and social media accounts, and she applied to art shows, art walks, and galleries. After about a year, her efforts paid off, and she started to get invitations for projects.

She has since exhibited her work in juried shows and galleries in the Boston, Orlando, and Seattle areas and has received commissions for public art from several cities in Washington. She even has a piece in the permanent gallery at Japan’s Sobana Museum.

Despite her artistic success, Mercado says she eventually missed the problem-solving and patient care involved in clinical work. She started tinkering with her schedule and settled on a roughly 60-40 split in favor of medicine.

In addition to seeing patients, she continues to pursue art projects, working mostly with acrylics and mixed media on canvas and with digital illustration; her style reflects her experiences with children and her observations of wildlife and folk art around the world, especially in Japan.

“I’ve found a space where I’m happy,” she says, “and where it feels a little bit more balanced for me.”

This story also appears in the July/August issue of MIT Alumni News magazine, published by MIT Technology Review

Yunha Hwang

Education 

  • PhD, 2024, Evolutionary and Organismic Biology, Harvard University
  • MS, 2018, Earth Systems, Stanford University
  • B.Sc, 2018, Computer Science, Stanford University

Research Summary

Microbial genomes encode the largest molecular, biochemical, and functional diversity on Earth. We focus on developing machine learning models and experimental approaches to discover and design novel biological functions. We integrate computation with expertise in evolution, ecology, and biochemistry to characterize and harness the functional potential of microbes.

A shining light in the lab

Sriram “Sri” Srikant was known for insightful questions and irrepressible love of the pursuit of knowledge.

Lillian Eden | Department of Biology
July 24, 2025

Sriram “Sri” Srikant, a postdoctoral Scholar in the Laub Lab in the Department of Biology at MIT, succumbed to cancer in March. He was 35.

Srikant received a degree in Chemical Engineering with a minor in chemistry from the Indian Institute of Technology Madras in 2011, and a PhD in Molecular and Cellular Biology from Harvard University in 2019. Among many accomplishments, Srikant was awarded an HHMI International Student Research Fellowship and a Peralta Prize for an outstanding dissertation proposal, both in 2013.

Srikant is described by mentors and colleagues alike as brilliant — a remarkable researcher who was both knowledgeable and approachable and whose enthusiasm was a bright beacon to all who had the chance to know him.

“There’s a blues line that I love, ‘Let the Midnight Special shine the ever lovin’ light on me,’” says Harvard College Professor Andrew Murray, one of Srikant’s thesis advisors. “For me, Sri was that Midnight Special, and we were lucky to have his ever lovin’ light shine on us.”

Academics are often equally motivated by a mix of a love of the work and a desire to succeed, whether it be by publications, grants, or high-impact findings. According to colleagues, however, Srikant’s passion came entirely from his need to know more.

“He told me once that ‘A life without science wouldn’t be worth living,’” said Dia Ghose, PhD ’24, a graduate student in the Laub Lab. “He wanted to move his career forward so he could keep doing science, but he didn’t care about impressing people. He just loved science and wanted to keep doing it.”

In the face of a terminal diagnosis, Srikant kept coming into the lab until his illness made it impossible. His marks on Building 68, however, remain — people are and will continue using the strains he built, the technique he developed, and the expertise he was so generous in sharing.

“There’s so many reminders of him, which is how it should be, because he contributed so much,” Ghose says. “He’s living on in the lab, and we’re still using everything that he gave us every day.”

The generosity of Sri Standard Time

As a graduate student at Harvard, Srikant pursued his thesis work in a joint PhD in the labs of both Murray and Professor of Molecular and Cellular Biology Rachelle Gaudet.

“The experiments in Rachelle’s lab failed utterly, and those in mine failed miserably, but gave enough glimmers of possibility for him to make a series of technical innovations to turn something that looked hopeless into a very nice paper,” recalls Murray. “There was no part of science he wasn’t curious about, there was nothing he wouldn’t discuss, and there was no technical challenge he wouldn’t take on.”

In the Laub Lab, Srikant developed an experimental evolution approach to studying phage, the viruses that infect bacteria. Srikant set up an experimental pipeline to explore how phages can evolve to overcome anti-phage defense systems in bacteria. He was also investigating the broader mechanisms of how phage genomes evolve, and the types of mutations they acquire. In the case of recombination between co-infecting phages, he was developing a new methodology to study exactly how recombination between different phages occurs.

The experimental evolution approach swept through not just the lab at MIT but across the world, and Srikant assisted other labs in implementing his process.

“He was this incredibly selfless, generous guy who was always willing to help out other people,” says Michael Laub, Salvador E. Luria Professor and HHMI Investigator. “He also had this incredible encyclopedic knowledge and memory about all aspects of phages, and he was constantly drawing on that to help people with their projects.”

Srikant was so generous with his time and expertise that he was usually on “SST” or “Sri standard time”—which was, often, running late. He would declare he was heading out or needed to start experiments, and then engage in hours-long conversations with lab mates on topics ranging from physics to visa issues.

Srikant’s hobbies included reading papers from other fields — he was, simply put, interested in the pursuit of knowledge. If he wasn’t an expert on some topic, he could spend hours studying it, just in case he could be helpful. After ChatGPT was released, lab mates joked that ChatGP-Sri was more knowledgeable, had more reliable answers, and was usually available 24/7, says Tong Zhang, PhD ’24, another graduate student in the Laub Lab.

Srikant’s sole area of ignorance was seemingly was pop culture. He didn’t know who Taylor Swift was, and only knew of Lady Gaga from the one time she wore a meat dress more than a decade ago—which, Ghose noted, was a rather niche reference.

Always curious, never quiet

Murray recalls an incident when he was flying from Boston to San Francisco with Srikant, discussing science every minute of the flight. Srikant was so passionate about the subject that his neighbor felt the need to shush him repeatedly, which Srikant took in stride, saying, with a smile, “People have been telling me to be quieter my entire life, and they’re probably right!”

From his first year at Harvard to his final days in the Laub Lab, Srikant was known for his boundless curiosity. Murray says that it’s a rare thing, after a department seminar, for students to ask questions, but Srikant would always put his hand up. That habit continued through graduate school and at science and lab meetings during his too-brief time at MIT.

“It was remarkable,” Laub says. “After any talk, he always had the most probing, incisive, and really helpful questions, across very broad fields.”

Every time he asked a question, whether it was in class during his time at Harvard or at the Building 68 research retreat on the cape, Srikant would begin with, “One of the things I’m curious about.” Ghose says the phrase became something akin to a meme in the lab, and Srikant even commemorated the colloquialism with a bracelet that read ‘I’m curious.’

“For a person that brilliant and knowledgeable, Sri was so special. His impact on me and others will last forever,” Zhang says. “I have always been, and I will continue, looking up to him, honoring his passion for science, his brilliance as a scientist, and his kindness and generosity as a great friend.”